There remains substantial agreement among the international community on many aspects of the contemporary UN drug control regime. However, diverging views on the non-medical and non-scientific use of a range of controlled substances make drug policy an increasingly contested and transitionary field of multinational cooperation.
This report provides an analysis of the INCB report, specifically focusing on the report's foreword, thematic chapter, the Bolivia issue, and misinterpretations and omissions of key drug policy issues by the INCB.
Uruguay may be poised to become the first country to opt for a state controlled and legally regulated cannabis market for medical as well as recreational purposes, including cultivation and distribution.
The Global Network for Public Interest Law is seeking nominations for the second annual European Award for Partnership in the Public Interest, which will recognize the best pro bono legal project (or projects) undertaken jointly between a non-governmental organization and a law firm in Europe.
In this presentation, IDPC called for integrated drug strategies, with an increased focus on public health, social inclusion and economic development, through robust institutional structures at the UN level.
As always, the CND represents an intensive period of engagement for IDPC; preparations involved producing practical and logistical material to support the civil society presence at the event, as well as the planning of IDPC side events and strategic interventions, briefings and orientation…
The GuardianMixmag drugs survey followed last Sunday's Observer article which reported that mephedrone is more popular now than when it was banned. What is clear and confirmed in the drugs survey, is that banning mephedrone was at best ineffective. It is therefore heartening that member states at…
Welcome to the second edition of the IDPC Drug Policy Guide. The Guide brings together global evidence and examples of best practice to provide guidance on the review, design and implementation of national drug policies.